74
Participants
Start Date
April 13, 2021
Primary Completion Date
October 31, 2025
Study Completion Date
November 30, 2025
Viltolarsen
Received during weekly intravenous infusions
Queensland Children's Hospital, Brisbane
The Childrens Hospital at Westmead, Westmead
CHU de Quebec Research Centre, Québec
Hospital de Niños Roberto del Rio, Santiago
Pontificia Universidad Católica de Chile, Santiago
Chinese PLA General Hospital, Beijing
Hunan Children's Hospital, Changsha
Children's Hospital of Fudan University, Shanghai
Shenzhen Children's Hospital, Shenzhen
Fakultni nemocnice Hradec Kralove, Nový Hradec Králové
Agia Sofia Children's Hospital, Athens
Hippokration General Hospital of Thessaloniki, Thessaloniki
Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore, Rome
National Center of Neurology and Psychiatry, Tokyo
Instituto Nacional de Pediatría, Mexico City
Leids Universitair Medisch Centrum, Leiden
Radboud Universitair Medisch Centrum, Nijmegen
New Zealand Clinical Research Ltd., Auckland
Rikshospitalet, Oslo
Russian National Research Medical University, Moscow
"Saint Petersburg State Paediatric Medical University based at Consultative and Diagnostic Centre", Saint Petersburg
Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk
Pusan National University Yangsan Hospital, Pusan
Seoul National University Hospital, Seoul
Hospital Sant Joan de Deu, Barcelona
Hospital Universitario La Paz, Madrid
Yeditepe University Kosuyolu Hospital, Istanbul
Birmingham Heartlands Hospital, Birmingham
Royal Hospital for Children, Glasgow
Royal Manchester Children's Hospital, Glasgow
University College London Institute of Child Health, London
Lead Sponsor
Collaborators (1)
Nippon Shinyaku Co., Ltd.
INDUSTRY
NS Pharma, Inc.
INDUSTRY